- Home
- STKS vs GNLX Comparison
STKS vs GNLX Comparison
Compare STKS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- GNLX
- Stock Information
- Founded
- STKS 2004
- GNLX 2001
- Country
- STKS United States
- GNLX United States
- Employees
- STKS N/A
- GNLX N/A
- Industry
- STKS Restaurants
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- GNLX Health Care
- Exchange
- STKS Nasdaq
- GNLX Nasdaq
- Market Cap
- STKS 104.0M
- GNLX 103.6M
- IPO Year
- STKS N/A
- GNLX 2023
- Fundamental
- Price
- STKS $2.90
- GNLX $2.43
- Analyst Decision
- STKS Buy
- GNLX Strong Buy
- Analyst Count
- STKS 3
- GNLX 4
- Target Price
- STKS $5.83
- GNLX $18.25
- AVG Volume (30 Days)
- STKS 143.9K
- GNLX 163.2K
- Earning Date
- STKS 11-07-2024
- GNLX 11-14-2024
- Dividend Yield
- STKS N/A
- GNLX N/A
- EPS Growth
- STKS N/A
- GNLX N/A
- EPS
- STKS N/A
- GNLX N/A
- Revenue
- STKS $541,400,000.00
- GNLX $8,000.00
- Revenue This Year
- STKS $104.25
- GNLX N/A
- Revenue Next Year
- STKS $30.52
- GNLX N/A
- P/E Ratio
- STKS N/A
- GNLX N/A
- Revenue Growth
- STKS 63.49
- GNLX N/A
- 52 Week Low
- STKS $2.83
- GNLX $1.60
- 52 Week High
- STKS $6.45
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- STKS 38.74
- GNLX 40.85
- Support Level
- STKS $2.83
- GNLX $2.48
- Resistance Level
- STKS $3.53
- GNLX $2.80
- Average True Range (ATR)
- STKS 0.20
- GNLX 0.19
- MACD
- STKS -0.04
- GNLX -0.03
- Stochastic Oscillator
- STKS 21.92
- GNLX 15.38
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.